Michael S. Saag is a physician and prominent HIV/AIDS researcher at the University of Alabama at Birmingham. He holds the Jim Straley Chair in AIDS Research, is Director of the Division of Infectious Disease and of the William C. Gorgas Center for Geographic Medicine, and Director of the Center for AIDS Research.

During the past decade, Michael S. Saag conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Michael S. Saag" are "HIV Infections" (2 trials). Many other conditions were trialed in "Michael S. Saag" in a lesser frequency.

Most popular intervention types in "Michael S. Saag" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Indinavir sulfate" (1 trials), "Lamivudine" (1 trials), "Nelfinavir mesylate" (1 trials) and "Stavudine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Michael S. Saag" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Michael S. Saag". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Michael S. Saag, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Michael S. Saag, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".